ArticleJournal of ophthalmic inflammation and infection2018
Rituximab and bilateral HSV epithelial keratitis in a patient with mucous membrane pemphigoid.
Article in Journal of ophthalmic inflammation and infection, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 12 citations in OpenAlex.
- Ocular involvement in oral vesiculobullous diseases: A review on reported cases in the literature.The Saudi dental journal · 2024Review
- Herpes simplex keratitis: A brief clinical overview.World journal of virology · 2024Review
- Case report: Mucous membrane pemphigoid with complicated autoantibody profile indicating the necessity of comprehensive diagnostic methods and the contribution of IgA autoantibodies.Frontiers in immunology · 2023Article
- Incidence and Risk Factors of Bilateral Herpetic Keratitis: 2022 Update.Tropical medicine and infectious disease · 2022Review
- Ocular manifestations of herpes simplex virus.Current opinion in ophthalmology · 2019Review
- Should Patients with Hidradenitis Suppurativa Undergo LASIK?Ophthalmology and therapy · 2019Article
- Special Care in Lichen Planus Patients Undergoing LASIK: A Review Article.Medical hypothesis, discovery & innovation ophthalmology journal · 2019Review
- Peripheral B Cell Deficiency and Predisposition to Viral Infections: The Paradigm of Immune Deficiencies.Frontiers in immunologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundB cell depleting therapy is widely used for lymphoproliferative diseases and immune-mediated disorders, including mucous membrane pemphigoid. The latter is an autoimmune blistering disease affecting predominantly the mucosae potentially associated with devastating complications.
methodsA 71-year-old patient with severe mucous membrane pemphigoid involving ocular, oral pharyngeal and laryngeal involvement is described. To control the disease, the patient was given rituximab therapy in combination with oral corticosteroids. He subsequently experienced an epithelial herpes simplex virus keratitis in one eye and 3 months later in his fellow eye. Topical treatment with ganciclovir resulted in prompt recovery.
resultsFor the first time, a correlation between rituximab and bilateral epithelial herpes simplex virus keratitis is described.
conclusionsAlthough rituximab is a promising biologic agent for the treatment of autoimmune diseases, it bears the risk of reactivation of viral infections, including the onset of herpes simplex virus keratitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.